Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 11Liver Neoplasms 7Lung Neoplasms 5Urinary Bladder Neoplasms 4Small Cell Lung Carcinoma 4Diabetes Mellitus, Insulin-Dependent, 12 4Pancreatic Neoplasms 3Neoplasms 3Colorectal Neoplasms 3Cholangiocarcinoma 3Biliary Tract Neoplasms 3Adenocarcinoma Of Esophagus 3Neoplasm Metastasis 2Mesothelioma, Malignant 2Mesothelioma 2Fallopian Tube Neoplasms 2Carcinoma 2Urothelial Cancer 1Urethral Neoplasms 1Ureteral Neoplasms 1Unresectable Hepatocellular Carcinoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Malignancies 1Seminoma 1Rare Diseases 1

Interventions

tremelimumab 1durvalumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Malignancies × tremelimumab × 1 year × Clear all
NCT02537418 2026-03-27

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Canadian Cancer Trials Group

Phase 1 Active not recruiting
153 enrolled

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡